Stallergenes opened its own operations in the United Kingdom in 2011.

The subsidiary is owned by our parent company which is based in Antony, on the outskirts of Paris, in France. A key player in its market, Stallergenes is a global company which has set itself the goal of working alongside healthcare professionals to advance management of respiratory allergies and achieve long-term improvements in quality of life for allergic patients.

Our main focus in the United Kingdom is the planning and preparation for the future launch of our registered tablet immunotherapy products.